Zobrazeno 1 - 10
of 1 913
pro vyhledávání: ''
Autor:
Kiki C. Andree, Menno Tamminga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Leon W.M.M. Terstappen, Anouk Mentink, Hilda van den Bos, Peter M. Lansdorp, Wim Timens, Diana C.J. Spierings
Publikováno v:
British journal of cancer, 126, 409-418. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be ob
Autor:
Stephanie Tuminello, Naomi Alpert, Rajwanth R. Veluswamy, Arvind Kumar, Jorge E. Gomez, Raja Flores, Emanuela Taioli
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
BMC Cancer
BMC Cancer
Background It has been postulated that patient’s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit, however, has not yet been explored using patient-level data, where potential confounders, as well as histologic type, c
Autor:
Márcia Datz Abadi, Paula de Mendonça Batista, Rodrigo Buzzatti Peixoto, Carlos Gil Ferreira, Erica Regina Cerqueira, Lucas Miyake Okumura, Fernando Brandão Serra
Publikováno v:
JCO Global Oncology
PURPOSE Non–small-cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 80%-90% of the cases. In Brazil, between 2018 and 2019, lung cancer was ranked as the second most frequent cancer among men and the fourth among wome
Autor:
Gary Middleton, Alex G. Richter, Akshay J Patel, Ti-Myen Tan, Jonathan M. Blackburn, Babu Naidu
Publikováno v:
British Journal of Cancer
Background Lung cancer is the leading cause of cancer-related death worldwide. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. Despite careful case selection, a sig
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.
Autor:
Erica L. Carpenter, Stephanie S. Yee, Taylor A. Black, Allysia J. Mak, Austin L. Chien, Jamie Rosenstein, Carin R. Espenschied, Katie Quinn, Rebecca J. Nagy, Benjamin A. Silva, Sharyn I. Katz, Charu Aggarwal, Roger B. Cohen, Corey J. Langer, Aditi P. Singh, Martina I. Lefterova, Jeffrey C. Thompson, Christine Ciunci, Joshua Bauml, Lesli A. Kiedrowski
Publikováno v:
JCO Precis Oncol
PURPOSEAlthough the majority of patients with metastatic non–small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setting, predicting which patients will experience a dur
Autor:
Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga
Publikováno v:
Anticancer Research. 41:5137-5145
BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T
Autor:
Yoichi Nakanishi, Yuichiro Ohe, Akihiko Gemma, Kazuhiko Nakagawa, Ayumi Akamatsu, Takahiko Sakamoto, Nobuyuki Yamamoto
Publikováno v:
Cancer Science
Postmarketing surveillance of Japanese patients with unresectable, previously treated, advanced or recurrent non‐small‐cell lung cancer treated with nivolumab was undertaken during the conditional approval period. The study aim was to evaluate th
Autor:
Yuxuan Xiao, Qiran Zhang, Yalun Li, Chengdi Wang, Hanlin Gong, Jingwei Li, Jiayang Wu, Lujia Song
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
BMC Cancer
BMC Cancer
Background The advent of immune checkpoint inhibitors (ICIs) therapy has resulted in significant survival benefits in patients with non-small-cell lung cancer (NSCLC) without increasing toxicity. However, the utilisation of immunotherapy for small-ce
Publikováno v:
Clinical Lung Cancer. 22:e646-e653
Background Non-small cell lung cancer (NSCLC) is responsible for the most cancer-related deaths in the United States. A better understanding of treatment-related disparities and ways to address them are important to improving survival for patients wi